8K Just Came Out ! They Are Still In Talks For A Deal With Sosei !
Quote: Item 1.01. Entry into Material Definitive Agreement.
On August 15, 2017, the registrant extended the deadline to consummate the terms of the previously announced binding term sheet with Sosei Corporate Venture Capital Ltd. for the establishment of a new Japanese corporation for the clinical development and commercialization of the registrant’s PLX-PAD cell therapy product in Japan, until December 31, 2017.
Final Neupogen ARS LP studies with DOD/Barda concluded early for outstanding efficacy, and the Gov. ordered stockpiling before the end of their trial. Good benchmark with which to compare R-18's speeed/progress.
Hey everyone, hit most discussed. Allo has been talking about a controller for over a year now.
IMO, Pluristem Will Receive One For PLX-R18 As A MCM For ARS !
How the Government Will Pay Companies to Develop Biodefense Products and Win Lucrative PRVs
Lets see how transparent management is. When are we going to have an investor day, where mgt. can make a presentation and answer shareholder questions.
@allo. Um... wouldn't the controller want more shares at 'deal time', not less? They must have done the math to determine how many shares they can short, for years now, vs. doing nothing and waiting like the rest of us...? They would have to know the date of the deal right? Nooooo. If they knew the date of the deal... they would be quietly accumulating, not shorting... The LOGIC doesn't work with your Controller conspiracy theory... If you believe this is going to the moon, look for patterns of accumulation , by insiders and >1% holders...not shorts.
Will Pluristem Therapeutics Inc.’s (PSTI) PLX-R18 Help Treat Acute Radiation Syndrome? H.C. Wainwright Weighs in
Analyst Swayampakula Ramakanth of H.C. Wainwright is out with a research note on Pluristem Therapeutics ...
Positive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthritis Research & Therapy ....yesterday's news ....in my view, what's good for the goose is good for the gander ... success for one stem cell company will raise the profile for others ...glta
Nice News! If this study shows PLX is effective with prophylactic administration? Then this is a blockbuster!
Hi Michael. Pluristem may be making headlines, but there are many other competitors who are right there with us. Some may be ahead, others behind. But there are many players who have received significant funding contracts of $50 million plus for their development. We had our trials paid for by NIH. Below is a list of 4 of them.
Neupogen (Amgen) Already purchased for stockpiling Hemamax (Neumedicines) up to $273 million contract CLT-008 (Cellerant) $153 million contract AEOL-10150 (Aeolus) $118 million contract
Feels like Pluristem went about this the wrong way. Why have all these companies received significant funding from Barda? How much would our trials would have cost that were paid for by NIH? Don’t think it would come close to these amounts, but I don’t know.
I don’t know if we will get any sort of stockpiling sales yet. Zami was talking about funding of $50 million or somewhere thereabout if I remember correctly. I could see BARDA giving us that amount for the continuation of our trials, like others obviously got. But who knows.
One thing for sure is we got lots of competition. Look into some of these products and you can see how far along they are.
Just writing this as it gets deleted on IH. I have been posting on IH board for a little while now, and my posts kept on getting deleted. There is a moderator there, Midastouch, who is the one who is deleting my posts. This guy, also posts on Brainstorm and Elbit Vision systems board, and lives in Israel. These two companies, were previous companies where our upper management and directors came from. It is appauling that my posts on Pluristem get deleted over there, by someone who in the very least, follows companies where our upper management is, and has come from.
@Allo. What you are suggesting @allo. is fraud and traceable. Given PSTI's history on this very issue, do you really think it is happening again??? Really? "They Would Get All Their Shares At A Pre-Determined Set Price From The Company !" - Poor leadership & Competition are CONTROLLING this stock.
finally...now hopefully this back and forth between a few people will end and we can talk about making money
Finally some good news, been waiting for this 3 years bleeding my #$%$ off.2018 is our year.hopefully in 2019 we are 13$ and north.
SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = Undiscovered low float stock with 1000% upside Potential and more .GLTA
Soleno therapeutics (SLNO)
Market Cap $18 Million Cash: $8 Million Price $0.37
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
here we go......
The upside potential for PSTI just got a whole lot more interesting. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awe-some*sto-ck*s is the one i like best.
Yet another study announced today. by the D.O.D. I've been watching PSTI for 5 years now and it looks like they are another 5 years away from making any real money on PLX-R18 or anything else . All of these studies and no one approves or buys any of their drug candidates.Its frustrating as hell. I'm sick of hearing that another new study is being announced. Whenever you here about a new study being initiated, what it really means is that the D.O.D. is not yet ready to recommend , approve or buy anything until they research this stuff for another year or two etc. . It's frustrating as hell.
ONE " FIRE-CRACKER " AND THIS BABY IS GOING TO THE MOON !!! LOAD UP - IF YOU CAN.